Utilization, spending, and price trends for short- and long-acting beta-agonists and inhaled corticosteroids in the Medicaid program, 1991-2010

American Health and Drug Benefits

Volumn 4, Issue 3, 2011, Pages 140-149

  Chiu, Shih Feng ^a   Kelton, Christina M L ^b   Guo, Jeff Jianfei ^a   Wigle, Patricia R ^a   Lin, Alex C ^a   Szeinbach, Sheryl L ^c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; FORMOTEROL FUMARATE; LEVALBUTEROL; MOMETASONE FUROATE; ORCIPRENALINE; PIRBUTEROL ACETATE; SALBUTAMOL; SALBUTAMOL SULFATE; SALMETEROL XINAFOATE; TERBUTALINE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VENCERIL;

ARTICLE; ASTHMA; DRUG COST; DRUG MARKETING; DRUG UTILIZATION; HEALTH PROGRAM; HUMAN; MEDICAID; MEDICAL SERVICE; PRESCRIPTION; PREVALENCE; REIMBURSEMENT; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

EID: 80051482748     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Klomp H, Lawson JA, Cockcroft DW, et al. Examining asthma quality of care using a population-based approach. CMAJ. 2008;178:1013-1021.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2009. www.ginasthma.com/download.asp?intId=411. Accessed March 9, 2011.
3. Mannino DM, Homa DM, Pertowski CA, et al. Surveillance for asthma-United States, 1960-1995. MMWR CDC Surveill Summ. 1998;47:1-27.
4. Senthilselvan A. Prevalence of physician-diagnosed asthma in Saskatchewan, 1981 to 1990. Chest. 1998;114:388-392.
5. Masoli M, Fabian D, Holt S, Beasley R; for the Global Initiative for Asthma (GINA) program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469-478.
6. Gaugris S, Sazonov-Kocevar V, Thomas M. Burden of concomitant allergic rhinitis in adults with asthma. J Asthma. 2006;43:1-7.
7. Celikel S, Isik SR, Demir AU, et al. Risk factors for asthma and other allergic diseases in seasonal rhinitis. J Asthma. 2008;45:710-714.
8. Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33:897-906.
9. Szeinbach SL, Rodriguez-Monguio R, Baran RW, Williams PB. Sleep disorders and chronic constipation: relation to other co-morbidities? Open Allergy J. 2010;3:29-34.
10. Dean BB, Calimlim BM, Kindermann SL, et al. The impact of uncontrolled asthma on absenteeism and health-related quality of life. J Asthma. 2009;46:861-866.
11. Juniper EF. Quality-of-life considerations in the treatment of asthma. Pharmacoeconomics. 1995;8:123-138.
12. Bousquet J, Knani J, Dhivert H, et al. Quality of life in asthma. I. Internal consistency and validity of the SF-36 questionnaire. Am J Respir Crit Care Med.1994;149:371-375.
13. L. Asthma prevalence, health care use and mortality: United States, 2003-2005. CDC National Center for Health Statistics, 2006. www.cdc.gov/nchs/data/hestat/asthma03-05/asthma03-05.htm. Accessed March 9, 2011.
14. Weiss KB, Sullivan SD. The economic costs of asthma: a review and conceptual model. Pharmacoeconomics. 1993;4:14-30.
15. Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.
16. National Heart, Lung, and Blood Institute. Morbidity & Mortality: 2009 Chart Book on Cardiovascular, Lung, and Blood Diseases. www.nhlbi.nih.gov/resources/docs/cht-book.htm. Accessed March 9, 2011.
17. Ho SM. Environmental epigenetics of asthma: an update. J Allergy Clin Immunol.2010;126:453-465.
18. Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med. 2006;355: 2226-2235.
19. Sawicki GS, Vilk Y, Schatz M, et al. Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs. J Asthma. 2010; 47:574-580.
20. National Heart, Lung, and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma. 2007. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed February 28, 2011.
21. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. 2007. www.who.int/gard/publications/GARD_Manual/en/index.html. Accessed March 9, 2011.
22. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990;336:1391-1396.
23. Mcivor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med. 1998;158:924-930.
24. Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med. 2004;140:802-813.
25. Hasford J, Virchow JC. Excess mortality in patients with asthma on long-acting beta2-agonists. Eur Respir J. 2006;28:900-902.
26. Price AH, Clissold SP. Salbutamol in the 1980s: a reappraisal of its clinical efficacy. Drugs. 1989;38:77-122.
27. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326:501-506.
28. Pearce N, Beasley R, Crane J, et al. End of the New Zealand asthma mortality epidemic. Lancet. 1995;345:41-44.
29. Rider NL, Craig TJ. A safety review of long-acting beta2-agonists in patients with asthma. J Am Osteopath Assoc. 2006;106:562-567.
30. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001;285:2583-2593.
31. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest. 2003;124:70-74.
32. Lemanske RF Jr, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA. 2001;285:2594-2603.
33. Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J Soc Med. 2010;103:98-106.
34. Shaya FT, Dongyi D, Akazawa MO, et al. Burden of concomitant asthma and COPD in a Medicaid population. Chest. 2008;134:14-19.
35. Broder MS, Gutierrez B, Chang E, et al. Ratio of controller to total asthma medications: determinants of the measure. Am J Manag Care. 2010;16:170-178.
36. Centers for Medicare & Medicaid Services. State drug utilization data. www.cms.hhs.gov/MedicaidDrugRebateProgram/SDUD/list.asp#TopOfPage. Accessed March 9, 2011.
37. Chen Y, Kelton CML, Jing Y, et al. Utilization, price, and spending trends for antidepressants in the US Medicaid program. Res Soc Adm Pharm. 2008;4:244-257.
38. Jing Y, Klein P, Kelton CML, et al. Utilization and spending trends for antiretroviral medications in the US Medicaid program from 1991 to 2005. AIDS Res Ther.2007;4:22.
39. Bureau of Labor Statistics. Consumer price index-all urban consumers. US city average. All items. www.bls.gov/cpi. Accessed March 6, 2011.
40. American Lung Association. Trends in asthma morbidity and mortality. February 2010. www.lungusa.org/finding-cures/our-research/trend-reports/asthma-trendreport.pdf. Accessed on March 9, 2011.
41. Krieger JW, Song L, Takaro TK, Stout J. Asthma and the home environment of low-income urban children: preliminary findings from the Seattle-King County healthy homes project. J Urban Health. 2000;77:50-67.
42. Centers for Medicare & Medicaid Services. Data compendium, 2010 edition. www.cms.gov/DataCompendium/14_2010_Data_Compendium.asp#TopOfPage. Accessed March 9, 2011.
43. National unemployment rate. http://data.bls.gov/timeseries/LNS14000000. Accessed March 6, 2011.
44. Kemp JP, Bierman CW, Cocchetto DM. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring. Ann Allergy. 1993;70:316-322.
45. Derom EY, Pauwels RA, Van der Straeten ME. The effect of inhaled salmeterol on methacholine responsiveness in patients with asthma up to 12 hours. J Allergy Clin Immunol. 1992;89:811-815.
46. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1997; 10:815-821.
47. Ameredes BT, Calhoun WJ. Levalbuterol versus albuterol. Curr Allergy Asthma Rep. 2009;9:401-409.
48. Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest. 2003;123: 128-135.
49. Gawchik SM, Saccar CL, Noonan M, et al. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol. 1999;103:615-621.
50. Crader M, Borkowski J. Nebulized albuterol versus levalbuterol in pediatric and adult patients: a review. Formulary. 2009;44:108-118.
51. Jaeschke R, O'Byrne PM, Mejza F, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med. 2008;178:1009-1016.
52. Jing Y, Kelton CML, Guo JJ, et al. Price, utilization, and spending for antipsychotic medications in the Medicaid program. Drug Benefit Trends. 2007;19:27-41.
53. Guo JJ, Kelton CML, Pasquale MK, et al. Price and market-share competition of anti-ulcer gastric medications in the Ohio Medicaid market. Int J Pharm Med. 2004; 18:271-282.
54. Kaiser Commission on Medicaid and the Uninsured. State Medicaid outpatient prescription drug policies: findings from a national survey, 2005 update. www.kff.org/medicaid/upload/State-Medicaid-Outpatient-Prescription-Drug-Policies-Findings-from-a-National-Survey-2005-Update-report.pdf. Accessed March 9, 2011.
55. Owens PL, Thompson J, Elixhauser A, Ryan K. Care of children and adolescents in U.S. hospitals, 2003. HCUP Fact Book No. 4, publication No. 04-0004. Rockville, MD: Agency for Healthcare Research and Quality. 2003. www.ahrq.gov/data/hcup/factbk4/factbk4.pdf. Accessed April 25, 2011.
56. Berger WE. Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Ann Allergy Asthma Immunol. 2003;90:583-592.